MaxCyte Inc (MXCT) Rating Reiterated by Panmure Gordon
MaxCyte Inc (LON:MXCT)‘s stock had its “buy” rating restated by Panmure Gordon in a research report issued to clients and investors on Tuesday. They currently have a GBX 170 ($2.22) price objective on the stock. Panmure Gordon’s target price would indicate a potential upside of 101.18% from the stock’s previous close.
MaxCyte (LON:MXCT) opened at 83.00 on Tuesday. The firm’s 50-day moving average price is GBX 84.50 and its 200 day moving average price is GBX 82.05. The company’s market capitalization is GBX 36.08 million. MaxCyte has a 52 week low of GBX 75.00 and a 52 week high of GBX 86.38.
MaxCyte Company Profile
MaxCyte, Inc focuses on cell-based medicines. The Company’s cell modification technology, Flow electroporation, is used for discovery, development and manufacture of small molecule, biologic and cell-based therapeutics. The Company’s products include instruments, processing assemblies and insourcing services.
Receive News & Ratings for MaxCyte Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.